The Canadian government has given a startup the green light to export psychedelic substances to Australia for medicinal use. Optimi Health Corp. has been tasked with the distribution of pills infused with psilocybin, derived from magic mushrooms, and MDMA, as sanctioned by the health department.
The growing demand surpasses the local magic mushrooms Ontario. Other countries are following Canada’s lead and beginning to examine and authorize the use of serotogenic substances for medical applications.
Feel free to buy psychedelics online in Canada and tap into your inherent potential through trustworthy sources.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to ship magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions spread over five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a small Vancouver-based company, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and secure a competitive edge.
Seven firms have exported psilocybin, MDMA, or both, exclusively for clinical trial purposes. A spokesperson from Canada’s health department couldn’t confirm if these exports were for regular patient use and chose not to reveal the companies involved due to security reasons.
This accomplishment positions Optimi as one of a few global suppliers, with the market currently favoring clinical over recreational use.
What’s in the Pill?
While the company hasn’t disclosed the specific mushroom variety used in the pill, they are known to work with diverse strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town, with a population of roughly 3,000, is situated three hours to the east of Vancouver.
The Intersection of Australia and Psychedelic Mushrooms
Approximately 1 in 5 Australians between the ages of 16 and 85 may encounter a mental health issue. PTSD (post-traumatic stress disorder) has the potential to affect 11% of Australians at any point in their lifetime, and anxiety disorders are prevalent in 17% of the population.
There is a broad spectrum of treatments for mental health conditions, but not all are effective for every person. Those who don’t respond to certain treatment modalities might struggle to find a method that helps them, increasing their susceptibility.
Understanding the Process
Australia has led the way in psilocybin use, allowing licensed psychiatrists to employ this controlled substance in treating PTSD and depression that have proven resistant to traditional treatments.
In a groundbreaking decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA declared these substances safe when used in a medically supervised setting for patients with severe mental disorders.
This advancement has been transformative for numerous mental health professionals and researchers. The utilization of these substances will be meticulously overseen; it’s not as simple as ingesting a pill and departing.
The treatment protocol typically consists of three sessions over a span of five to eight weeks. Each session lasts approximately eight hours, with the therapist being present with the patient the entire time.
Canada’s Role in Psilocybin Research
Canada has become a leading center for psilocybin research, greatly advancing our understanding of this substance. Health Canada, in collaboration with various institutions, is at the forefront of investigating psilocybin’s therapeutic potential in treating diverse mental health conditions.
Research institutions are no longer required to classify these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
The increased accessibility to substances previously deemed harmful enables researchers to expand their knowledge of their potential benefits to numerous individuals.
A Recurring Trend
In the 1950s, the potential of this field began to be seen as a way to tackle mental health problems and substance addiction, including alcoholism. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer led the early research in this field at the Saskatchewan Mental Hospital in Weyburn. Then-premier Tommy Douglas, who granted the medical community significant freedom to investigate their medical hypotheses, oversaw significant progress.
Dr. Osmond and Dr. Hoffer began conducting research on LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected turns, with the pair advocating for medical personnel, including doctors, nurses, and support staff, to experiment with these substances.
Canadian Institutes of Health Research
Under the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will promote a deeper understanding of the advantages of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, has made this possible.
Further Psychedelic Research
Psychiatrists in Vancouver have started a phase III clinical trial of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder (PTSD). The treatment involves three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. Researchers consider this trial to be of historical importance as it’s the first clinical investigation of an illicit substance.
This is the first major breakthrough in the field of psychedelic substances in over four decades.
A Closer Look at Psilocybin
Psilocybin, a psychedelic compound that naturally occurs in certain types of mushrooms, is metabolized into psilocin upon consumption. It is psilocin that stimulates the serotonin 5-HT2a receptors in the cortical pyramidal cells of the brain, which act as the main processing centers.
Local authorities are investigating this compound for its potential to alleviate depression, anxiety, addiction, and distress at the end of life by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective Against Depression, PTSD, and More?
The key ingredient interacts with multiple brain areas, which may make it effective for numerous mental conditions. Countless patients in Canada and Australia have already been treated using this therapy and the results have shown promise, with minor side effects such as temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially activates serotonin receptors, especially the 5-HT2A subtype, which plays a key role in emotional response and mood regulation.
- Alteration of the Default Mode Network (DMN): It reduces the DMN’s activity, fostering introspection, promoting flexible thinking, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Areas: The antidepressant effects of this compound are due to its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressed individuals, there’s often a reduced response to emotional stimuli. This compound enhances the response to positive emotional stimuli in the right amygdala while reducing or normalizing the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: It fosters feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience can help individuals safely confront and deal with deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College Research from London suggests that it can lead to enduring beneficial changes, such as increased well-being, improved life satisfaction, and spiritual growth.
What Can You Discover in Your Local Magic Mushroom Shops?
Interested in how this substance might impact your mental health? You can explore magic mushroom stores to find a product that suits your needs.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, inspires creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Encourages better wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Stimulates clear thinking, creativity, and concentration. Contains a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
Worldwide Acceptance of Psilocybin
Canada isn’t the only country supporting the use of magic mushrooms for mental health conditions. Countries like Australia are also accepting the use of these hallucinogens to treat ailments like depression and PTSD. They are obtaining high-quality psychedelic capsules from trustworthy sources. With proper supervision, patients can significantly improve their life quality. Shroom Delivery Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potential in enhancing mental health. Psilocybin interacts with serotonin 2A receptors and proves beneficial in treating depression and addiction.
Meanwhile, MDMA creates empathy and proves useful in PTSD therapy. It has potential in enhancing emotional processing and
Despite being classified as a controlled substance, it still exhibits therapeutic benefits.
Is this treatment accessible to all Australians?
In Australia, not everyone can access this treatment. An individual’s eligibility is determined after an assessment, which takes into account factors such as existing heart conditions and history of psychosis. Only patients who haven’t found success with conventional treatments for conditions like depression, anxiety, or PTSD can access this treatment.
What is the impact of Canada exporting mushrooms?
Canada is strategically positioning itself to lead the psychedelic market, much like its position in the cannabis industry. This move could encourage more companies to produce high-quality products. As a result, Canada could establish itself as a major player in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. It would also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Interesting Articles You Might Enjoy:
